Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home ASX Page 21

News & Views

Latest News

Category: ASX

See all

Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University

ASX, News,

Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry...

Read more

Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call

ASX, News,

Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with...

Read more

Activity Report and Sales Note to Accompany Appendix 4C

ASX, News,

Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging...

Read more

AGM Notice of Meeting – Telix Pharmaceuticals Limited

ASX, News,

Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May...

Read more

Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic

ASX, News,

Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal...

Read more

Telix Completes Acquisition of European Radiopharmaceutical Production Facility

ASX, News,

Telix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe,...

Read more

Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

ASX, News,

Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer...

Read more

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

ASX, News,

Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for...

Read more

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

ASX, News,

Telix Pharmaceuticals Limited Releases Annual Report Year Ending...

Read more

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

ASX, News,

Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s...

Read more

Posts pagination

1 … 20 21 22 23

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings